Nano PGE sub(1) promoted the recovery from spinal cord injury-induced motor dysfunction through its accumulation and sustained release

The effect of Nano PGE sub(1) (nanoparticles containing prostaglandin E sub(1)) on spinal cord injury (SCI) was investigated in rat model. Nano PGE sub(1) significantly and dose-dependently promoted the recovery from SCI-induced motor dysfunction, and the potency of Nano PGE sub(1) was comparable with successive treatment of Lipo PGE sub(1), and was superior to single treatment of Lipo PGE sub(1). Distribution study revealed that Nano PGE sub(1) sustained longer in the blood. In the injured spinal cord, gradual accumulation and longer retention were observed. Lipo PGE sub(1) was also accumulated with time, but over 10 fold less. It should be noted that over 80 fold more of PGE sub(1) were detected in Nano PGE sub(1)-treated injured spinal cord as compared with that in normal ones. Nano PGE sub(1)-treated injured spinal cord had less lesion cavity with increased MBP expression. Also, HGF production significantly increased as compared with that of SCI control. These findings could lead to the conclusion that Nano PGE sub(1) had the therapeutic potential for SCI, which might be partly ascribed by the efficient distribution of Nano PGE sub(1) to the injured spinal cord. The sustained release of PGE sub(1) would have increased HGF production, and both would have promoted cell survival and endogenous repair.